Angelini Pharma is an international group, leader in health care and well-being, committed to help patients, doctors and caregivers in the fight against diseases with constant and prevalent attention in the areas of Pain and Inflammation and Mental Health. Angelini Pharma has made research its core business to improve patients' health and quality of life.
INCIPIT, Italian Network for Paediatric Clinical Trials, is a non profit consortium composed by the Italian main children's hospitals, the largest departments of paediatrics and national and international paediatric therapeutic networks coordinated by Italian institutions with the aim to support the planning, conduction and completion of all types of clinical studies in the paediatric population.
In this context, Angelini and INCIPIT, sharing the scope to promote high quality research on drugs, are now launching the first edition of call for proposals - Angelini for Future 2021- to support independent research projects proposed by European investigators working in public or private non-profit healthcare organizations. In this joint collaboration, Angelini allocates 300 K€ to fund up to two research projects either in late preclinical phase or in early clinical phase and INCIPIT provides the expertise to prepare the call, to manage the evaluation process of the research projects and to perform monitoring of the scientific results.
Therapeutic area: This call is in support of research project focusing on rare diseases (in Europe a disease is considered to be rare when it affects 1 person per 2000) or on conditions with high unmet medical needs in CNS with the aim to identify and to develop new uses of existing drugs in the paediatric population
Host Institution: Only research proposals submitted by Investigators employed by public and private non-profit Research Institutions (Academia, Research Foundation and non-profit organizations) are eligible.
Pre-proposal deadline: 31 March 2021
https://eatris.eu/insights/angelini-for-future-2021-call-for-proposals/